Martin Ferris
Question:214. Deputy Martin Ferris asked the Minister for Health the status of children with cystic fibrosis who are waiting for treatment with the drug Kalydeco; and if he will make a statement on the matter. [38100/16]
View answerThursday, 1 December 2016
Questions (214)
Written answers
The manufacturer submitted an application to the HSE to have Ivacaftor, brand name Kalydeco, reimbursed for the treatment of cystic fibrosis patients aged 2 years and older weighing less than 25kg. In March of this year the HSE requested that the NCPE carry out a health technology assessment of the applicant’s economic dossier on the cost effectiveness of this treatment. In the submitted economic dossier the manufacturer estimates that there are 18 patients eligible for early ivacaftor treatment.